Detalhe da pesquisa
1.
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.
Hepatol Res
; 47(3): E142-E151, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27153246
2.
Faldaprevir and deleobuvir for HCV genotype 1 infection.
N Engl J Med
; 369(7): 630-9, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23944300
3.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Ann Hepatol
; 15(3): 333-49, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27049487
4.
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
J Hepatol
; 62(6): 1246-55, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25559324
5.
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Antimicrob Agents Chemother
; 59(2): 1282-91, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25512403
6.
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Liver Int
; 35(2): 417-21, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25263751
7.
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Antimicrob Agents Chemother
; 58(2): 698-705, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24217701
8.
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Antimicrob Agents Chemother
; 58(6): 3429-36, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709256
9.
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
J Pharmacol Exp Ther
; 351(2): 403-12, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25204339
10.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Hepatology
; 57(6): 2143-54, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359516
11.
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology
; 57(6): 2155-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504636
12.
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.
Antimicrob Agents Chemother
; 57(10): 4727-35, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23856779
13.
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
J Hepatol
; 57(1): 39-46, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22414766
14.
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Gastroenterology
; 141(6): 2047-55; quiz e14, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21925126
15.
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
J Hepatol
; 54(6): 1114-22, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21145839
16.
A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.
Toxicol Pathol
; 39(3): 496-501, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21441227
17.
Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
BMC Infect Dis
; 9: 203, 2009 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20003457
18.
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
PLoS One
; 11(12): e0168544, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28030579
19.
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
PLoS One
; 11(8): e0160668, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27494410
20.
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Eur J Gastroenterol Hepatol
; 28(8): 923-6, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140229